申请人:Biorex Laboratories Limited
公开号:US04412992A1
公开(公告)日:1983-11-01
The present invention provides a pharmaceutical composition for treating ulcerative colitis containing at least one compound of the general formula: ##STR1## wherein X is an --SO.sub.2 -- or --CO-- group and R is either an unsubstituted or substituted non-heterocyclic aromatic ring system or is a radical of the general formula --(CH.sub.2).sub.n --Y, in which Y is a hydroxyl group, an unsubstituted or substituted amino group or a carboxylic or sulphonic acid group and n is a whole number of from 1 to 6 and in which one or more hydrogen atoms in the alkylene radical can be replaced by unsubstituted or substituted amino groups or alkyl radicals and in which the --(CH.sub.2).sub.n --Y radical is either attached directly to the nitrogen atom or via a benzene ring; and/or containing at least one ester thereof and/or at least one non-toxic, pharmaceutically acceptable salt thereof, in admixture with a solid or liquid pharmaceutical diluent or carrier. Furthermore, the present invention provides a process for preparing the compounds of the above-given general formulae and also provides a method of treating ulcerative colitis.
本发明提供了一种治疗溃疡性结肠炎的药物组合物,其包含至少一种符合以下通式的化合物:
其中X是--SO.sub.2 --或--CO--基团,R是未取代或取代的非杂环芳香环系统,或者是符合以下通式--(CH.sub.2).sub.n --Y的基团,其中Y是羟基、未取代或取代的氨基或羧基或磺酸基团,n是1到6之间的整数,其中烷基基团中的一个或多个氢原子可以被未取代或取代的氨基团或烷基基团替代,--(CH.sub.2).sub.n --Y基团可以直接连接到氮原子或通过苯环连接;和/或包含至少一种酯化物和/或至少一种非毒性、药学上可接受的盐,与固体或液体药用稀释剂或载体混合。此外,本发明提供了一种制备上述通式化合物的方法,以及一种治疗溃疡性结肠炎的方法。